[	(
Quantifying	VBG
plasma	NN
levels	NNS
of	IN
transforming-growth-factor-beta1	NN
in	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
]	)
.	.

OBJECTIVE	NN
:	:
Transforming	VBG
growth	NN
factor	NN
ss1	NN
(	(
TGF-ss1	NN
)	)
is	VBZ
one	CD
of	IN
the	DT
key	JJ
profibrotic	JJ
mediators	NNS
in	IN
the	DT
pathogenesis	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

The	DT
purpose	NN
of	IN
this	DT
study	NN
was	VBD
to	TO
investigate	VB
the	DT
prognostic	JJ
value	NN
of	IN
quantifying	VBG
TGF-ss1	NN
levels	NNS
in	IN
patients	NNS
with	IN
IPF	NN
.	.

PATIENTS	NNS
AND	CC
METHODS	NNS
:	:
We	PRP
conducted	VBD
a	DT
prospective	JJ
study	NN
of	IN
29	CD
IPF	NN
patients	NNS
and	CC
27	CD
healthy	JJ
controls	NNS
.	.

Enzyme-linked	JJ
immunosorbent	JJ
assays	NNS
were	VBD
used	VBN
to	TO
quantify	VB
TGF-ss1	NN
levels	NNS
.	.

RESULTS	NNS
:	:
Mean	NN
(	(
SD	NN
)	)
TGF-ss1	NN
levels	NNS
were	VBD
significantly	RB
higher	JJR
in	IN
the	DT
IPF	NN
patients	NNS
than	IN
in	IN
the	DT
control	JJ
subjects	NNS
(	(
11.1	CD
[	(
7.5	CD
]	)
ng/mL	NN
vs	CC
4	CD
[	(
2.4	CD
]	)
ng/mL	NN
;	:
P	NN
<	JJR
.01	CD
)	)
.	.

Weak	JJ
inverse	JJ
correlations	NNS
were	VBD
observed	VBN
between	IN
TGF-ss1	NN
levels	NNS
and	CC
both	CC
forced	VBD
vital	JJ
capacity	NN
and	CC
total	JJ
lung	NN
capacity	NN
.	.

Thirteen	CD
IPF	NN
patients	NNS
were	VBD
evaluated	VBN
at	IN
8	CD
(	(
1.2	CD
)	)
months	NNS
(	(
range	NN
,	,
5-9	CD
months	NNS
)	)
.	.

The	DT
mean	NN
TGF-ss1	NN
level	NN
was	VBD
18.2	CD
(	(
15	CD
)	)
ng/mL	NN
and	CC
there	EX
were	VBD
no	DT
significant	JJ
differences	NNS
with	IN
respect	NN
to	TO
the	DT
initial	JJ
measurement	NN
of	IN
11.1	CD
(	(
7.5	CD
)	)
ng/mL	NN
.	.

No	DT
correlation	NN
was	VBD
observed	VBN
between	IN
changes	NNS
in	IN
respiratory	JJ
function	NN
and	CC
changes	NNS
in	IN
TGF-ss1	NN
levels	NNS
.	.

CONCLUSIONS	NNS
:	:
Although	IN
plasma	NN
levels	NNS
of	IN
TGF-beta1	NN
were	VBD
high	JJ
in	IN
the	DT
patients	NNS
with	IN
IPF	NN
,	,
they	PRP
do	VBP
not	RB
appear	VB
to	TO
be	VB
a	DT
useful	JJ
prognostic	JJ
marker	NN
of	IN
disease	NN
activity	NN
or	CC
therapeutic	JJ
response	NN
.	.

